Solution

Precision Empowering Pharmaceutical Innovation: Multi-Dimensional Particle Characterization Technologies Driving Drug R&D and Quality Control

In the pharmaceutical field, the size, morphology, and distribution of particles directly impact drug efficacy, safety, and stability. Whether it is the crystal habit of active pharmaceutical ingredients (APIs), the potential risks of sub-visible particulate matter, or the dissolution behavior in generic drug bioequivalence studies, particle size control remains a core metric贯穿 across the entire lifecycle of R&D, manufacturing, and quality control. The pharmacopoeias of China, the United States, and Europe (ChP, USP, EP) have all established clear provisions for particle characterization methods. Meanwhile, the frontiers of current pharmaceutical innovation — such as antibody-drug conjugates (ADCs), lipid nanoparticles (LNPs), mRNA vaccines, and continuous manufacturing — pose even greater challenges to particle analysis technologies. Traditional particle sizing methods often suffer from limitations including single-dimensional information, inability to distinguish particle types, susceptibility to bubble interference, and lack of real-time process monitoring capabilities.

With years of deep expertise in particle characterization technologies, Mipu Technology offers a comprehensive portfolio covering laser diffraction, static image analysis, microflow imaging, nanoparticle size analysis (DLS + Zeta), and in-situ probe-based online imaging/laser diffraction. We are committed to providing the pharmaceutical industry with accurate, efficient, and multi-dimensional data support across the entire lifecycle — from R&D to quality control — empowering companies to meet regulatory requirements and seize the high ground in innovation.

The Strategic Significance of Particle Characterization in the Pharmaceutical Industry

1.1 Regulatory-Driven Quality Control

Particle size distribution is a critical component of drug quality standards. Pharmacopoeias in China, the US, and Europe have established clear requirements for particle characterization across various dosage forms:

• Chinese Pharmacopoeia (ChP): Chapter 0903 "Determination of Insoluble Particulate Matter" includes light obscuration and microscopic counting methods; Chapter 0982 "Determination of Particle Size and Particle Size Distribution" includes sieving, sedimentation, laser diffraction, and light scattering methods.

• United States Pharmacopoeia (USP): <429> "Laser Diffraction Measurement of Particle Size," <776> "Optical Microscopy," <788> "Particulate Matter in Injections," <787> "Subvisible Particulate Matter in Therapeutic Protein Injections," <789> "Particulate Matter in Ophthalmic Solutions," among others.

• European Pharmacopoeia (EP): 2.9.31 "Laser Diffraction," 2.9.37 "Optical Microscopy," among others.

These regulations not only specify testing methods but also impose stringent requirements for instrument performance qualification, system suitability, and data integrity.

1.2 Technology-Driven Innovation in R&D

Three major trends in current pharmaceutical innovation are driving new demands for particle characterization technologies:

• Rise of Complex Formulations: Complex injectables such as liposomes, microspheres, nanocrystals, and ADC drugs require more sophisticated characterization tools, as particle properties directly impact efficacy and safety.

• Adoption of Continuous Manufacturing: The FDA and EMA are vigorously promoting continuous manufacturing, which necessitates Process Analytical Technology (PAT) for real-time monitoring of material attributes — making in-situ particle monitoring a critical enabler.

• Growth of Personalized Medicine: Small-batch, multi-product manufacturing models require analytical instruments capable of handling micro-samples and enabling rapid method switching.

1.3 The Leap from Particle Size Measurement to Particle Characterization

Particle characterization is by no means limited to simply "measuring size." Particle shape (acicular, plate-like, spherical), surface texture, aggregation state, and particle type (e.g., protein aggregates, silicone oil droplets, glass shards) all have profound effects on formulation performance. Consequently, particle size analyzers based on a single measurement principle can no longer meet the complex demands of modern pharmaceutical development and manufacturing. Adopting multi-dimensional, multi-principle particle analysis technologies — with both offline and online capabilities — has become an essential strategy for pharmaceutical companies to meet regulatory requirements and enhance their core competitiveness.

Core Technology Matrix: Six Principles, Full-Spectrum Application Coverage

Mipu Technology offers a range of testing techniques that comply with pharmacopoeia requirements, enabling flexible selection based on sample characteristics and application scenarios.

2.1 Laser Diffraction (Predominantly Dry Method, Supplemented by Wet Method)

• Principle: Based on Mie scattering theory. When a laser beam illuminates particles, different particle sizes produce scattered light at different angles. Detectors collect the signals, and scattering models are used to calculate the particle size distribution (D10, D50, D90, SPAN value, etc.).

• Pharmacopoeia Basis: ChP 0982, USP <429>, EP 2.9.31.

• Advantages: Broad measurement range (0.01–3500 μm), fast analysis (seconds), excellent repeatability (error ≤ ±1%).

• Application Characteristics in Small Molecule Drugs: Most small molecule APIs are hygroscopic or prone to degradation upon contact with water; therefore, the dry method is the primary approach, using compressed air to disperse the powder directly without liquid contact. The wet method is used as a supplement only for a limited number of water-stable, non-hydrolyzing samples. The dry method also avoids issues such as solvent selection and dispersant interference, meeting the efficiency and compliance requirements of small molecule quality control.

• Applications: High-throughput quality control of small molecule APIs, excipients, and oral solid dosage forms.

2.2 Static Image Analysis (Particle Size & Shape Analyzer)

• Principle: Dry powder samples are uniformly spread on a glass slide. A high-resolution microscope camera captures images of stationary particles, and AI algorithms analyze morphological parameters such as particle size, circularity, aspect ratio, and convexity for each particle.

• Pharmacopoeia Basis: ChP 0982 (Microscopic Counting Method), USP <776>, EP 2.9.37.

• Advantages:

• Direct visualization of true particle morphology, distinguishing acicular/plate-like/spherical particles and identifying agglomerates.

• Particularly suited for R&D customers: requires extremely low sample volumes (only 1–5 mg), avoiding waste of valuable APIs and intermediates; dry powder spreading without liquid dispersion preserves the original particle state.

• Enables rapid evaluation of crystallization and milling process outcomes, providing morphological evidence for early formulation screening.

• Applications: Early-stage R&D micro-samples, API crystal habit studies, milling process optimization, excipient morphology assessment.

2.3 Microflow Imaging (MFI)

• Principle: Combines microfluidic technology with high-magnification microscopic imaging. Liquid samples flow through a micro-channel, and extended-depth-of-field imaging captures sub-visible particles (0.5–100 μm). AI algorithms identify particle morphology, count, and size, distinguishing drug particles from impurities.

• Pharmacopoeia Basis: ChP 0903, USP <787>/<788>/<789>.

• Advantages: Precisely differentiates bubbles, silicone oil droplets, protein aggregates, fibers, metal particles, etc. Outputs particle concentration (particles/mL), meeting the sub-visible particle testing requirements for protein injectables.

• Applications: Insoluble particulate matter monitoring and traceability for injectables, biologics, eye drops, ADCs, liposomes, etc.

2.4 Nanoparticle Size Analyzer (DLS + Zeta Potential)

• Principle: Based on Dynamic Light Scattering (DLS), which detects the Brownian motion of nanoparticles to calculate hydrodynamic particle size. Simultaneously, Electrophoretic Light Scattering (ELS) is used to measure Zeta potential for assessing dispersion stability.

• Pharmacopoeia Basis: Compliant with relevant nanomedicine quality control requirements.

• Advantages: Measurement range 1 nm–3 μm; provides PDI (polydispersity index). A Zeta potential absolute value ≥30 mV indicates a stable system.

• Applications: Particle size and stability evaluation for nanomedicines such as liposomes, nanoparticles, nanosuspensions, and mRNA-LNPs.

2.5 Probe-based In-situ Imaging / Laser Diffraction (Dedicated to Small Molecule Crystallization)

• Principle: Optical probes are inserted directly into the small molecule crystallization reactor to capture real-time images or scattered light signals of particles during the crystallization process, eliminating the need for sampling and avoiding disruption of crystal morphology. AI algorithms analyze particle size, shape, and crystal form consistency in real time.

• Regulatory Support: As a Process Analytical Technology (PAT), this approach aligns with the FDA Guidance for Industry: Process Validation and ICH Q13 (Continuous Manufacturing).

• Advantages: Real-time monitoring of nucleation, growth, breakage, and agglomeration; captures crystal form transitions; supports closed-loop process control.

• Applications: Small molecule API crystallization process development, scale-up, and continuous manufacturing.

2.6 Static Image Analysis (Dedicated to Micro-Samples in Early-Stage R&D)

• Principle: The same as conventional static image analysis, but optimized for minimal sample consumption — requiring only 1–5 mg of dry powder sample to complete a test, avoiding sample waste.

• Advantages: Ideal for micro-scale APIs and intermediates in early R&D and clinical trial stages. Requires no complex dispersion; direct spreading and testing maximize preservation of precious samples.

• Applications: New drug screening, early-stage crystallization process optimization, rapid particle shape assessment for micro-samples.

In-Depth Analysis of Five Core Application Scenarios

3.1 Sub-Visible Particle Testing – The "Gatekeeper" of Injectable Safety

Regulatory Requirements: USP <788> stipulates that for injectables, particles ≥10 μm shall not exceed 25 particles/mL, and particles ≥25 μm shall not exceed 3 particles/mL. USP <787> requires that for protein injectables, protein aggregates be distinguished from non-proteinaceous particles.

Industry Pain Points: Traditional light obscuration methods cannot differentiate between air bubbles and real particles, nor can they identify particle types, leading to false positives or an inability to trace the root cause.

Mipu Solution: Microflow Imaging Analyzer

• High-Sensitivity Identification and Bubble Rejection: Employs morphological algorithms to precisely distinguish bubbles from solid particles.

• Particle Classification and Traceability: Automatically classifies silicone oil droplets, protein aggregates, glass shards, fibers, etc., providing direct evidence for deviation investigations.

• Concentration Measurement and Stability Monitoring: Reports particle counts per milliliter, enabling prediction of formulation aggregation trends.

Case Study: A biopharmaceutical company observed an increase in ≥10 μm particles in stability samples of a high-concentration monoclonal antibody injection. Microflow imaging revealed that the particles consisted of two categories: silicone oil droplets and protein aggregates. The latter increased with rising temperature, guiding formulation optimization and container selection, ultimately facilitating successful regulatory submission.

3.2 API Milling and Crystal Engineering – The Key to Dissolution and Efficacy

Regulatory Requirements: ICH Q6A requires that for poorly soluble drugs, particle size control specifications be established.

Industry Pain Points: Crystal habit of the active pharmaceutical ingredient (API) affects powder properties, while conventional laser diffraction methods cannot provide morphological information.

Mipu Solution: Laser Diffraction (Predominantly Dry Method) + Static Image Analysis in Tandem

• Rapid QC via Laser Diffraction: Uses dry dispersion to test API powder directly, avoiding solvent effects. Measures D10, D50, and D90 to ensure batch-to-batch milling process consistency.

• Process Optimization via Image Analysis: Particularly suited for valuable R&D-stage samples – requires only milligram-level API. Quantifies aspect ratio, circularity, and convexity to guide crystallization processes; identifies acicular crystals or agglomerates.

Case Study: An anti-HIV drug exhibited poor powder flowability after jet milling. While laser diffraction indicated acceptable D50 values, image analysis revealed a large number of acicular crystals intertwining. By reducing milling pressure and introducing a crystal habit modifier, equant particles were obtained, significantly improving flowability.

3.3 Dissolution Profile Development – The "Decoder" of In Vitro–In Vivo Correlation

Regulatory Requirements: Generic drug bioequivalence studies require similarity in dissolution profiles (f2 factor ≥ 50).

Industry Pain Points: Differences in dissolution behavior often stem from changes in API particle size distribution, which traditional dissolution testing cannot reveal.

Mipu Solution: Offline/Online Laser Diffraction for Dissolution Process Tracking

• Sampling at different dissolution time points to monitor particle size evolution, revealing disintegration and release mechanisms.

• Establishing "particle size – dissolution – absorption" in vitro–in vivo correlation (IVIVC) models.

Case Study: A sustained-release tablet using an HPMC matrix exhibited significant batch-to-batch dissolution variability. By employing microflow imaging to observe HPMC swelling behavior, it was found that swelling rates differed between batches. After establishing in-house control specifications, the variability was successfully resolved.

3.4 Container Closure Cleanliness and Compatibility Testing – Overlooked Invisible Contamination

Regulatory Requirements: USP <661> and <1660> require evaluation of container-closure system compatibility with drug products.

Industry Pain Points: Extractables from packaging materials (e.g., silicone oil droplets, glass shards) may pose safety risks.

Mipu Solution: Microflow Imaging Analyzer

• Rinsing the inner surface of containers, collecting and analyzing the rinse solution to automatically identify detached particle types.

• Monitoring changes in the count and size of extractables during long-term stability studies.

Case Study: A biological product packaged in pre-filled syringes showed increased particulate matter during stability testing. Microflow imaging identified the particles as predominantly silicone oil droplets, which intensified with rising temperature. The issue was resolved by switching to syringes with a low-silicone-oil coating.

3.5 Online Real-Time Monitoring of Crystallization Processes – A Process Breakthrough from "Black Box" to "Transparent"

Regulatory Support: FDA Guidance for Industry: Process Validation and ICH Q13 emphasize real-time monitoring of critical process parameters.

Industry Pain Points: Offline sampling fails to capture the true dynamics of crystallization, often leading to scale-up difficulties.

Mipu Solution: In-situ Probe-based Online Imaging / Laser Diffraction Analyzer

• Accurately determines nucleation point and induction time.

• Real-time tracking of crystal growth kinetics, crystal habit evolution, breakage, and agglomeration.

• Interfaces with control systems to enable closed-loop feedback control.

Case Study: During the scale-up of an innovative drug crystallization process from lab to pilot scale, the crystal morphology shifted from blocky to acicular, extending filtration time from 1 hour to 8 hours. By installing an in-situ probe, it was discovered that localized supersaturation during initial anti-solvent addition generated a large number of acicular crystal nuclei. After optimizing the addition point and agitation speed, the pilot scale successfully reproduced blocky crystals, and filtration time was restored to 1.5 hours.

Comprehensive Solution Architecture and Data Integrity

4.1 Full-Process One-Stop Service

Based on the different stages of pharmaceutical R&D and production, Mipu Technology provides methodological consulting and technical support (summarized in the table below):

4.2 Data Integrity Assurance

Our entire suite of instrument software is fully compliant with FDA 21 CFR Part 11 requirements, featuring:

• Access Control: Three-tier (or higher) user privilege levels (Administrator, Operator, Reviewer) ensuring full operational traceability.

• Audit Trail: Automatic recording of all data modifications, method edits, and system setting changes.

• Electronic Signatures: Ensuring data authenticity, validity, and non-repudiation.

• Data Backup: Support for automated backup and database management.

• Compliant Reporting: Generation of test reports that meet ChP, USP, and EP standards.

5. Conclusion: The Leap from Particle Size Measurement to Particle Characterization

As a professional provider of particle characterization solutions, Mipu Technology understands that in the pharmaceutical field, a "particle" is far more than just a number. We offer a comprehensive set of six-dimensional characterization tools that integrate size, morphology, concentration, trends, particle type, and dynamic processes.

By combining the efficient quality control of laser diffraction (predominantly dry method for small molecules), the morphological insights of static image analysis (particularly suited for valuable micro-samples from R&D customers), the particle classification and counting of microflow imaging, the dispersion stability evaluation of nanoparticle size analyzers, and the in-situ process monitoring of probe-based systems, we empower pharmaceutical companies to:

• See Clearer: Gain deeper insights into the microscopic world of particles, revealing the relationship between morphology and function.

• Control Precisely: Optimize every process parameter to ensure batch-to-batch consistency.

• Use Safer: Ensure the safety and efficacy of every drug dose, safeguarding patient health.

• Understand Processes Better: Transform the crystallization "black box" into a transparent process, accelerating process development and scale-up.

• Achieve Compliance with Confidence: Fully meet the pharmacopoeia requirements of China, the US, and Europe, facilitating regulatory submissions.

• Accelerate Innovation: Empower cutting-edge fields such as ADCs, LNPs, and continuous manufacturing, helping you seize the high ground in innovation.

Mipu Technology remains committed to continuous innovation, leveraging our superior particle characterization technology to safeguard the quality of your pharmaceutical products.

Contact Mipu Technology today to obtain your customized pharmaceutical particle characterization solution.